BioCentury | Apr 14, 2020
Product Development

COVID-19 roundup: Can-Fite repurposing RA therapy; plus Brazilian chloroquine study points to cardiotoxicity, Athersys stem cell trial, Rutgers saliva test

...As Can-Fite begins testing the first ADORA3 agonist against COVID-19, the latest red flag for chloroquine...
...to start a pivotal trial of its cell therapy to treat moderate to severe COVID-19. Can-Fite BioPharma Ltd....
...hospitalized COVID-19 patients to receive either piclidenoson plus standard supportive care or supportive care alone. Can-Fite...
BioCentury | Jan 7, 2020
Financial News

BioIntervene takes on adenosine in pain, raises $30M

...explored for inflammation; it is one of several novel targets in early-stage testing for osteoarthritis. Can-Fite BioPharma Ltd....
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

...while also reducing the pain factor NGF to hit both the structural and functional endpoints. Can-Fite BioPharma Ltd....
...and understand the biological pathways that may be targeted,” said Rovati. Companies and Institutions Mentioned Can-Fite BioPharma Ltd....
BioCentury | Aug 10, 2018
Company News

China Medical gains rights to Can-Fite's ADORA3 agonists

...CF102) in Taiwan and China, including Hong Kong and Macau, from Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-A:CANF). Can-Fite...
...and is eligible for $14 million in regulatory milestones and $58.5 million in sales milestones. Can-Fite...
...non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD). Both compounds are adenosine A3 receptor (ADORA3) agonists. Can-Fite BioPharma Ltd....
BioCentury | Jan 20, 2017
Financial News

Can-Fite completes direct public offering

...Cancer and inflammatory disease company Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF) raised $5 million through the sale of...
...ordinary shares. H.C. Wainwright was the placement agent. Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF), Petah Tikva, Israel Alex Himes Can-Fite BioPharma Ltd....
BioCentury | Jul 18, 2016
Clinical News

Piclidenoson: Phase II data

...well tolerated. Can-Fite said that it sees “no immediate path forward in glaucoma” for CF101. Can-Fite BioPharma Ltd....
BioCentury | Oct 19, 2015
Financial News

Can-Fite completes direct public offering

Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF), Petah Tikva, Israel Business: Cancer, Infectious, Autoimmune Date completed: 2015-10-13 Type: Direct public offering Raised: $4.8 million Shares: 1.1 million Price: $4.35 Shares after offering: 13.8 million Placement agent:...
BioCentury | Sep 28, 2015
Financial News

Can-Fite completes direct public offering

Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF), Petah Tikva, Israel Business: Cancer, Infectious, Autoimmune Date completed: 2015-09-21 Type: Direct public offering Raised: $9 million Shares: 2.1 million Price: $4.35 Shares after offering: 12.7 million Placement agent:...
BioCentury | Sep 21, 2015
Clinical News

CF102 regulatory update

...FDA granted Fast Track designation to Can-Fite’s CF102 as a second-line treatment for hepatocellular carcinoma (HCC...
...in Phase II testing to treat HCC and has Orphan Drug designation in the U.S. Can-Fite BioPharma Ltd....
BioCentury | May 11, 2015
Clinical News

IB-MECA: Additional Phase II/III data

...week 32 of 27% vs. an undisclosed percentage for patients pretreated with systemic drugs (p=0.026). Can-Fite...
...of improving PASI 75 response rate at week 12 vs. placebo (see BioCentury, April 6). Can-Fite BioPharma Ltd....
Items per page:
1 - 10 of 116
BioCentury | Apr 14, 2020
Product Development

COVID-19 roundup: Can-Fite repurposing RA therapy; plus Brazilian chloroquine study points to cardiotoxicity, Athersys stem cell trial, Rutgers saliva test

...As Can-Fite begins testing the first ADORA3 agonist against COVID-19, the latest red flag for chloroquine...
...to start a pivotal trial of its cell therapy to treat moderate to severe COVID-19. Can-Fite BioPharma Ltd....
...hospitalized COVID-19 patients to receive either piclidenoson plus standard supportive care or supportive care alone. Can-Fite...
BioCentury | Jan 7, 2020
Financial News

BioIntervene takes on adenosine in pain, raises $30M

...explored for inflammation; it is one of several novel targets in early-stage testing for osteoarthritis. Can-Fite BioPharma Ltd....
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

...while also reducing the pain factor NGF to hit both the structural and functional endpoints. Can-Fite BioPharma Ltd....
...and understand the biological pathways that may be targeted,” said Rovati. Companies and Institutions Mentioned Can-Fite BioPharma Ltd....
BioCentury | Aug 10, 2018
Company News

China Medical gains rights to Can-Fite's ADORA3 agonists

...CF102) in Taiwan and China, including Hong Kong and Macau, from Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-A:CANF). Can-Fite...
...and is eligible for $14 million in regulatory milestones and $58.5 million in sales milestones. Can-Fite...
...non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD). Both compounds are adenosine A3 receptor (ADORA3) agonists. Can-Fite BioPharma Ltd....
BioCentury | Jan 20, 2017
Financial News

Can-Fite completes direct public offering

...Cancer and inflammatory disease company Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF) raised $5 million through the sale of...
...ordinary shares. H.C. Wainwright was the placement agent. Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF), Petah Tikva, Israel Alex Himes Can-Fite BioPharma Ltd....
BioCentury | Jul 18, 2016
Clinical News

Piclidenoson: Phase II data

...well tolerated. Can-Fite said that it sees “no immediate path forward in glaucoma” for CF101. Can-Fite BioPharma Ltd....
BioCentury | Oct 19, 2015
Financial News

Can-Fite completes direct public offering

Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF), Petah Tikva, Israel Business: Cancer, Infectious, Autoimmune Date completed: 2015-10-13 Type: Direct public offering Raised: $4.8 million Shares: 1.1 million Price: $4.35 Shares after offering: 13.8 million Placement agent:...
BioCentury | Sep 28, 2015
Financial News

Can-Fite completes direct public offering

Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF), Petah Tikva, Israel Business: Cancer, Infectious, Autoimmune Date completed: 2015-09-21 Type: Direct public offering Raised: $9 million Shares: 2.1 million Price: $4.35 Shares after offering: 12.7 million Placement agent:...
BioCentury | Sep 21, 2015
Clinical News

CF102 regulatory update

...FDA granted Fast Track designation to Can-Fite’s CF102 as a second-line treatment for hepatocellular carcinoma (HCC...
...in Phase II testing to treat HCC and has Orphan Drug designation in the U.S. Can-Fite BioPharma Ltd....
BioCentury | May 11, 2015
Clinical News

IB-MECA: Additional Phase II/III data

...week 32 of 27% vs. an undisclosed percentage for patients pretreated with systemic drugs (p=0.026). Can-Fite...
...of improving PASI 75 response rate at week 12 vs. placebo (see BioCentury, April 6). Can-Fite BioPharma Ltd....
Items per page:
1 - 10 of 116